Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
Key facts
- Who runs it
- Stadtspital Zürich
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 13 people enrolled
- Started
- 10 Oct 2023
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Furosemide
- Metolazone
- Acetazolamide
- Record updated
- 14 February 2025
- Why it stopped
- Low recruitment in both centers
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Elective or emergency hospital admission with clinical diagnosis of acute heart failure
- One or more clinical signs of volume overload (i.e., peripheral edema, pleural effusion, jugular venous distension)
- Low diuretic efficacy in the first 2 hours after the standard screening dose Furosemide i.v. (i.e., urine volume < 300 ml and urine sodium concentration < 70 mmol/L)
- Plasma N terminal-proBNP level at enrolment > 1000 ng/L
- Signed Informed Consent form
Who cannot take part
- Maintenance treatment with Acetazolamide or Metolazone
- Concurrent diagnosis of acute coronary syndrome requiring urgent revascularization
- Severe chronic kidney disease (estimated glomerular filtration rate < 15 ml/min/1.73 m2) or use of renal replacement therapy at any time before study inclusion
- History of cardiac transplantation or ventricular assist device
- Allergy, intolerance or other contraindication against one of the study drugs
- Use of any non-protocol defined diuretic agent that cannot be stopped upon study inclusion except for sodium-glucose co-transporter-2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin) and mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone)
- Age below 18 years
- Systolic blood pressure < 90 mmHg
- Expected use of intravenous vasopressors (e.g., noradrenaline, adrenaline), inotropes (e.g., dobutamine, milrinone, levosimendan) at any time point during the study
- Severe liver dysfunction or cirrhosis at risk of hepatic encephalopathy
- Severe electrolyte disturbances or metabolic acidosis requiring specific intravenous treatment
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The P-VALUE-AHF trial is a multicenter, randomized, open-label, parallel-group trial on the diuretic and decongestive effects of different diuretic escalation strategies in patients with acute heart failure and diuretic resistance.
Read full original descriptionShow less
The main aims are
* to compare the diuretic efficacy of three therapeutic strategies in patients with acute heart failure and diuretic resistance. * to assess the improvement in clinical congestion and to compare the symptom-relief among the different treatment regimens
The 3 groups in the trial
- group FFExisting treatment, for comparison
Group FF will receive a doubled dose Furosemide i.v. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection.
Treatment: Furosemide
- group FMExisting treatment, for comparison
Group FM will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Metolazone will be administered orally.
Treatment: Furosemide and Metolazone
- group FAExisting treatment, for comparison
Group FA will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v. Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Acetazolamide (500mg) will be administered intravenously as a short infusion.
Treatment: Furosemide and Acetazolamide
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance (P-Value-AHF): A Multicentre, Randomized, Parallel-group, Open-label Trial
- Record updated
- 14 February 2025